Skip to main
MCRB

Seres Therapeutics (MCRB) Stock Forecast & Price Target

Seres Therapeutics (MCRB) Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 33%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 33%

Bulls say

Seres Therapeutics Inc. has demonstrated significant progress in its development pipeline, notably receiving positive feedback from the FDA regarding the Phase 2 plan for SER-155, which is likely to enhance expectations for regulatory approval. The company has solid financial health, with a cash runway extended to the second quarter of 2026 following a strategic 25% workforce reduction. Furthermore, ongoing efforts to secure a partnership for SER-155 underscore the company’s commitment to advancing its microbiome therapeutics platform, indicating potential for future growth.

Bears say

Seres Therapeutics Inc faces significant commercial risks, particularly concerning its product SER-109, which may generate revenues that fall short of both internal and consensus estimates, posing potential downside to the company's financial outlook. The requirement for additional safety or manufacturing data by the FDA could lead to delays in SER-109's approval process, further exacerbating these risks and impacting the company's market value. As a clinical-stage biotechnology company, Seres is expected to pursue additional capital raises, which could dilute current investors' stakes and negatively affect the current share price.

Seres Therapeutics (MCRB) has been analyzed by 3 analysts, with a consensus rating of Hold. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 33% predict a Strong Sell.

This aggregate rating is based on analysts' research of Seres Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Seres Therapeutics (MCRB) Forecast

Analysts have given Seres Therapeutics (MCRB) a Hold based on their latest research and market trends.

According to 3 analysts, Seres Therapeutics (MCRB) has a Hold consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Seres Therapeutics (MCRB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.